W. Kuhn

Leopoldina Krankenhaus Schweinfurt — Germany

Medicine · Health Sciences

40h-index9.8kcitations174works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(90), Neurological disorders and treatments(39), Genetic Neurodegenerative Diseases(26), Folate and B Vitamins Research(16), Nuclear Receptors and Signaling(15)

Publications174 total

Is Hypomethylation of the α‐Synuclein Gene in Parkinson's Disease Patients Related to Chronic Levodopa Intake?
Movement Disorders·2025
An Indirect Proof for Levodopa‐Induced Vitamin Deficiency in Parkinson's Disease
Movement Disorders·2023· 2 cited
Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease
Clinical Neuropharmacology·2023· 1 cited
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease
Movement Disorders·2023· 2 cited
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?
Expert Review of Clinical Pharmacology·2023· 16 cited
No Vitamin D Deficiency in Patients with Parkinson’s Disease
Degenerative Neurological and Neuromuscular Disease·2022· 3 citedOpen Access
Neurobiologie der Nahtoderfahrung
Universitätsverlag Kiel | Kiel University Publishing eBooks·2022Open Access
Amantadine for Treating Parkinson’s Disease
2022· 1 cited
Memantine for Treatment of Dementia
2022
Memantine for Treatment of Dementia
2022
No Vitamin D Deficiency in Patients With Parkinson’s Disease
Research Square (Research Square)·2021· 2 citedOpen Access
Complex motion series performance differs between previously untreated patients with Parkinson’s disease and controls
Journal of Neural Transmission·2021· 3 cited
Kinesiology training in patients with Parkinson’s disease: results of a pilot study
Journal of Neural Transmission·2020· 7 cited
Amantadine for Treating Parkinson’s Disease
2019· 3 cited
Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia
Expert Opinion on Pharmacotherapy·2019· 28 cited
Muss die bisherige BfR-Stellungnahme zur Risikobewertung revidiert werden?
NeuroTransmitter·2016
Basic science in Parkinson’s disease: its impact on clinical practice
Journal of Neurology·2011· 6 cited
No increased chromosomal damage in l-DOPA-treated patients with Parkinson’s disease: a pilot study
Journal of Neural Transmission·2010· 23 cited
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
Movement Disorders·2009· 41 cited
Cysteine elevation in levodopa‐treated patients with Parkinson's disease
Movement Disorders·2009· 29 cited
page 1 of 9Next →

Frequent Co-authors

H. Przuntek(25), Thomas Müller(21), Dirk Woitalla(14), Olaf Rieß(6), Jörg T. Epplen(5), Reiner Sprengelmeyer(5), Th. Büttner(5), Th. Müller(5), Th. M�ller(5), Rejko Krüger(4), Lüdger Schöls(4), G. Fuchs(4), Thomas Büttner(4), M. Gerlach(4), Daniela Berg(3), Thomas Postert(3), Brian Fowler(3), Carsten Saft(3), Peter Riederer(2), Andrew W. Young(2)